Peptomyc SL
Latest round
- Series A
Last raised
- Sep 2017
Total raised
- $6.2M
Investors
- 2
About Peptomyc SL
Peptomyc SL is a biotechnology company based in Spain, specializing in the development of innovative cancer therapies, particularly through its first-in-class MYC inhibitor, OMO-103. Founded in 2014, Peptomyc SL operates from its headquarters in Barcelona, Spain, focusing on the design and development of cancer treatments. The company was established by Laura Soucek, who has a history of involvement in biotechnology ventures. Peptomyc is at the forefront of cancer treatment innovation with its flagship product, OMO-103, a first-in-class MYC inhibitor. This mini-protein therapeutic directly targets MYC, a critical transcription factor that regulates tumor proliferation and survival, thereby addressing the high unmet medical needs of patients with cancers characterized by abnormal MYC activity. OMO-103 utilizes patented cell-penetrating properties to enable effective delivery to the nuclei of cancer cells, thereby facilitating targeted eradication while minimizing impact on healthy tissues. The product is currently being developed and tested in multiple clinical trials, including a Phase 2 trial for advanced osteosarcoma and a Phase Ib trial for pancreatic ductal adenocarcinoma (PDAC). Peptomyc primarily serves the oncology market, and its advancements in MYC inhibition are poised to benefit a broad range of cancer patients globally, particularly in regions such as North America and Europe. Peptomyc’s revenue model centers around the development and commercialization of its proprietary therapeutic products, specifically OMO-103. The transactions typically occur through partnerships with pharmaceutical companies and research institutions focused on oncology. As the company progresses through clinical trials, it aims to establish agreements for licensing and distribution of its products, enhancing its market presence. The financial structure may involve milestone payments, royalties on sales, and potential collaborations for co-development with strategic partners. Specific pricing plans and financial arrangements are tailored to the unique nature of the oncology therapeutics market, reflecting the crucial role of OMO-103 in addressing complex therapeutic challenges.9.
Who invested in Peptomyc SL
2 investors across 2 rounds
See all investors in Peptomyc SL
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Peptomyc SL
Who invested in Peptomyc SL?
Peptomyc SL has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Peptomyc SL raised?
Peptomyc SL has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Peptomyc SL last raise money?
Peptomyc SL's most recent round on record is a Series A, in Sep 2017.
What does Peptomyc SL do?
Peptomyc SL is a biotechnology company based in Spain, specializing in the development of innovative cancer therapies, particularly through its first-in-class MYC inhibitor, OMO-103.
Where is Peptomyc SL headquartered?
Peptomyc SL is headquartered in Barcelona, Spain.
Which VCs invest in companies like Peptomyc SL?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Peptomyc SL's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Peptomyc SL? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.